sever
immunocompromis
modifi
c
jimenez
p
et
al
pulmonari
infiltr
nonhiv
immunocompromis
patient
diagnost
approach
use
noninvas
bronchoscop
procedur
thorax
respiratori
tract
continu
expos
rang
micro
organ
normal
immun
respons
gener
prevent
caus
infect
henc
surpris
patient
significantli
impair
immun
frequent
develop
lung
infect
immunodefici
patient
also
frequent
sever
risk
factor
contribut
increas
risk
develop
pneumonia
includ
lowlevel
microaspi
ration
oropharyng
content
mucos
damag
caus
cytotox
therapi
underli
lung
damag
poor
nutrit
consequ
lung
infect
common
frequent
seriou
complic
patient
signific
impair
immun
system
pulmonari
infiltr
occur
patient
neutropenia
develop
chemotherapi
patient
undergo
hematopoiet
stem
cell
tran
plantat
hsct
die
result
pneumonia
rang
potenti
pathogen
caus
lung
infect
immunocom
promis
patient
much
broader
usual
patho
gen
caus
communityacquir
pneumonia
includ
organ
aspergillu
fumigatu
human
cytomega
loviru
cmv
diagnosi
infect
due
microb
difficult
requir
therapi
frequent
toxic
larg
number
potenti
pathogen
background
diseas
togeth
make
manag
lung
infect
immu
nocompromis
patient
consider
complex
use
invas
diagnost
test
bronchoscopi
frequent
necessari
chapter
focus
common
caus
pathogen
clinic
approach
pulmonari
infect
patient
sever
immunocompromis
chemotherapi
organ
transplant
hematolog
diseas
box
human
immunodefici
viru
hiv
fection
discuss
chapter
pneumonia
patient
milder
degre
immunosuppress
due
myeloma
low
dose
cytotox
therapi
diseasemodifi
agent
admini
tere
rheumatolog
condit
gener
manag
commun
hospitalacquir
pneumonia
rec
ognit
diseas
could
due
variou
opportunist
pathogen
discuss
chapter
potenti
pathogen
caus
lung
infect
immunocom
promis
patient
list
tabl
empir
therapi
activ
possibl
pathogen
feasibl
especi
given
potenti
toxic
treatment
henc
challeng
manag
patient
reduc
scope
differenti
diagnosi
includ
like
problem
thu
allow
rel
target
empir
therapi
identifi
type
invas
diagnost
test
use
provid
use
data
like
potenti
caus
pathogen
defin
ascer
tain
follow
clinic
radiolog
present
speed
onset
infect
type
durat
sever
patient
immun
defect
posit
result
microbiolog
studi
associ
factor
import
includ
recent
local
infect
epidem
patient
prophylaxi
regimen
ethnic
background
travel
histori
exact
type
immun
defect
determin
com
binat
diseas
treatment
receiv
fortu
nate
gener
predict
tabl
three
main
categori
immun
defect
absolut
function
neutro
penia
defect
cellmedi
immun
defici
antibodi
respons
clinic
less
sever
affect
categori
associ
particular
rang
pathogen
see
tabl
patient
neutropenia
mainli
risk
infect
extracellular
pathogen
pyogen
bact
ria
filament
fungi
defect
cellmedi
immun
tend
predispos
affect
patient
develop
infec
tion
intracellular
pathogen
virus
myco
bacteria
well
unusu
extracellular
infect
pneumocysti
pneumonia
pcp
defici
antibodi
respons
result
high
incid
infect
due
encap
sulat
bacteria
streptococcu
pneumonia
pesvirus
individu
patient
may
combin
immun
defect
exampl
lymphoma
caus
impair
cellmedi
immun
combin
neutro
penia
patient
receiv
chemotherapi
hsct
especi
allograft
recipi
particularli
asso
ciat
lung
complic
includ
infect
daunt
rang
pathogen
immun
defect
associ
hsct
depend
condit
regimen
type
graft
evolv
time
phase
preengraft
phase
day
transplant
prolong
neutro
penia
break
mucocutan
barrier
increas
risk
bacteri
fungal
infect
herp
simplex
viru
reactiv
also
occur
phase
phase
ii
immedi
postengraft
phase
around
day
transplant
infect
relat
primarili
impair
cellmedi
immun
includ
due
herpesvirus
particularli
cmv
pcp
unless
patient
given
pro
phylaxi
phase
iii
late
phase
beyond
day
common
pathogen
includ
herpesvirus
also
mark
increas
incid
infect
encapsu
late
bacteria
pneumonia
perhap
relat
impair
humor
immun
graftversushost
diseas
also
associ
ongo
suscept
aspergillu
phase
ii
iii
recipi
nonmyeloabl
hemato
poietic
stem
cell
transplant
substanti
differ
may
observ
phase
suscept
infect
phase
ii
iii
risk
diseas
communityacquir
respiratori
virus
elev
three
phase
combin
clinic
pattern
present
knowledg
patient
immun
defect
differenti
diag
nosi
like
pathogen
suggest
exampl
infec
tion
develop
rapidli
day
mark
rise
serum
inflammatori
marker
creactiv
protein
crp
pronounc
fever
focal
radiolog
chang
like
due
infect
pyogen
bacteria
patient
defect
cellmedi
immun
howev
widespread
ground
glass
infiltr
lung
develop
sever
day
could
repres
cmv
pneumon
pcp
gener
sever
prolong
immun
defect
greater
rang
possibl
caus
pathogen
less
typic
clinic
present
particular
pathogen
prompt
need
earli
invas
investig
initi
therapi
fail
effect
improv
furthermor
charact
diseas
dictat
sever
immun
defect
exampl
infect
due
filament
fungi
aspergillu
progress
faster
increas
sever
neutropenia
may
regress
becom
focal
neutrophil
count
recov
tabl
show
common
condit
consid
differ
present
lung
com
plicat
immunocompromis
patient
mani
patient
found
dual
patholog
process
either
involv
two
separ
pathogen
simultan
noninfect
fluid
overload
common
infect
prob
lem
respons
separ
element
clinic
pictur
previou
result
microbiolog
test
need
review
may
provid
strong
indic
caus
present
lung
infect
instanc
infect
indwel
defin
chapter
lymphomaleukemia
hematopoiet
stem
cell
transplant
hsct
aplast
anemia
solid
organ
transplant
caus
neutropenia
fewer
cellsml
inherit
disord
immun
function
eg
chronic
granulomat
diseas
recent
chemotherapi
highdos
corticosteroid
treatment
greater
mg
prednisolon
day
longer
treatment
immunosuppress
therapi
eg
tacrolimu
cyclosporin
treatment
cytotox
therapi
eg
cyclophosphamid
mycophenol
import
factor
need
taken
account
includ
patient
present
antibiot
prophylaxi
regimen
travel
histori
ethnic
background
patient
compliant
cotrimoxazol
prophylaxi
rare
develop
pcp
flu
conazol
prophylaxi
predispos
nonalbican
candida
infect
patient
certain
ethnic
background
perti
nent
travel
histori
risk
tb
endem
mycos
histoplasmosi
parasit
diseas
dissemi
nate
strongyloidiasi
final
patient
background
lung
structur
function
consid
exist
structur
abnorm
may
make
certain
pathogen
like
exampl
bronchiectasi
could
predispos
affect
person
pneumonia
caus
p
aeruginosa
figur
preexist
lung
caviti
aspergillu
infect
combin
new
respiratori
symptom
andor
new
radiolog
find
pyrexia
suggest
lung
infect
although
incident
radiolog
microbiolog
result
may
also
identifi
activ
lung
infect
asymptomat
patient
patient
undergo
care
clinic
assess
includ
review
previou
laboratori
radiolog
find
high
mortal
associ
lung
infect
immunocompro
mise
patient
requir
initi
rapidli
level
oxygen
character
immedi
risk
patient
also
suggest
like
pathogen
sever
hypoxia
like
bacteri
lobar
pneumonia
extens
pcp
viral
infect
chest
radiograph
essenti
first
line
investig
use
monitor
progress
howev
except
lobar
consolid
chest
radiograph
may
suffici
sensit
make
accur
assess
ment
pattern
lung
shadow
ultim
comput
tomographi
ct
scan
thorax
often
requir
ct
scan
approxim
sensit
chest
radiograph
identifi
lung
involv
also
defin
whether
new
chang
chest
radiograph
repres
consolid
nodul
ground
glass
infiltr
treeinbud
chang
patient
suspect
new
lung
infect
requir
blood
sputum
cultur
well
routin
blood
test
mani
case
nasopharyng
aspir
studi
identif
virus
assess
cmv
statu
serum
test
fungal
antigen
galactomannan
import
que
tion
respiratori
physician
util
inva
sive
investig
either
bronchoscopi
bronchoalveolar
lavag
bal
possibl
transbronchi
biopsi
percutan
radiolog
guid
biopsi
occas
surgic
biopsi
usual
videoassist
thoracoscop
surgeri
vat
test
use
depend
larg
extent
type
radiolog
presentationconsolid
diffus
ground
glass
infiltr
treeinbud
chang
nodulesin
accord
algorithm
provid
figur
respect
suggest
pro
tocol
balanc
likelihood
necess
posit
yield
clinic
probabl
particular
diseas
identifi
potenti
complic
investiga
tion
protocol
gener
guidanc
atyp
presen
tation
dual
patholog
uncommon
individu
patient
often
requir
modifi
approach
immunocom
promis
patient
also
high
risk
develop
rang
noninfect
caus
lung
diseas
includ
pulmo
nari
edema
idiopath
pneumonia
syndrom
ip
diffus
alveolar
hemorrhag
see
chapter
condit
alway
consid
differenti
diagnosi
new
lung
diseas
protocol
discuss
detail
next
rapidli
develop
focal
consolid
usual
due
bact
rial
pneumonia
initi
treat
empir
broadspectrum
antibiot
figur
like
reason
lack
improv
patient
condit
within
hour
infect
bacteria
resist
hsct
hematopoiet
stem
cell
transplant
bronchoscopi
fob
bal
percutan
ctguid
biopsi
mainli
evalu
dens
consolid
adjac
pleura
investig
also
necessari
patient
whose
pneumonia
fail
respond
secondlin
anti
biotic
therapi
subacut
chronic
consolid
sputum
microbiolog
cytolog
test
nondiag
nostic
progress
diseas
lack
definit
diagno
si
forego
test
surgic
biopsi
serious
consid
firstlin
antibiot
point
treatment
secondlin
antibiot
effect
like
resist
organ
start
consider
also
given
start
antibiot
ic
effect
mrsa
anaerob
pathogen
done
alreadi
patient
high
risk
invas
fungal
infect
especi
ct
evid
associ
nodular
diseas
patchi
infarctshap
consoli
dation
failur
firstlin
therapi
warrant
test
fungal
antigen
galactomannan
either
fiberopt
figur
comput
tomographi
ct
scan
thorax
show
dilat
thickwal
bronchi
characterist
bronchiectasi
patient
long
histori
chronic
lymphat
leukemia
immunoglobulin
defici
produc
purul
sputum
daili
cultur
grew
pseudomona
aeruginosa
b
chest
radiograph
obtain
patient
whose
clinic
present
includ
high
fever
product
cough
mark
hypoxia
show
consolid
mark
left
middl
zone
due
p
aeruginosa
pneumonia
respiratori
distress
syndrom
ard
drug
toxic
ip
associ
hsct
see
chapter
consequ
unless
nasopharyng
aspir
studi
identifi
respiratori
viral
infect
earli
fob
bal
possibl
transbron
chial
biopsi
attempt
often
howev
patient
markedli
hypox
increas
risk
associ
procedur
neg
result
fob
exclud
infect
caus
decis
need
taken
empir
treatment
versu
vat
lung
biopsi
ctguid
biopsi
investig
diffus
lung
diseas
carri
high
risk
complic
coupl
low
diagnost
yield
therefor
appropri
set
treeinbud
chang
figur
suggest
small
airway
patholog
immunocompromis
patient
differenti
diagnosi
ground
glass
infiltr
cen
trilobular
nodul
figur
wide
scope
includ
cmv
infect
viral
pneumonia
pcp
extens
bacteri
infect
noninfect
caus
acut
widespread
bilater
ground
glass
infiltr
hematopoiet
stem
cell
transplant
recipi
differenti
diagnosi
imag
appear
broad
scope
includ
cytomegaloviru
pneumonia
pneumocysti
pneumonia
drug
reaction
idiopath
pneumonia
syndrom
earli
invas
investig
typic
requir
even
though
widespread
lung
diseas
patient
like
signific
hypoxia
like
caus
respiratori
viru
infect
chlamydia
pneumonia
mycoplasma
pneumonia
especi
chang
focal
associ
nodular
chang
aspergillu
tracheobronch
subacut
chronic
chang
also
could
reflect
bacteri
infect
bronchiectasi
nontubercul
mycobacteria
infect
result
nasopharyng
aspir
studi
neg
earli
fob
bal
bronchial
biopsi
macroscop
inflam
bronchial
mucosa
perform
aspergillu
tracheobronch
usual
obviou
fob
readili
confirm
cultur
cytolog
examina
tion
bronchial
wash
bronchial
biopsi
infect
due
respiratori
virus
c
pneumonia
pneumonia
often
difficult
diagnos
usual
either
selflimit
ill
readili
control
macrolid
therapi
consider
differenti
diagnosi
pulmonari
nodul
includ
infect
aspergillu
invas
fila
mentou
fungi
nocardia
mycobacteria
figur
aspergillu
nocardia
tend
caus
small
number
nodul
wherea
mycobacteria
also
caus
larg
number
small
nodul
addit
bloodborn
spread
bacteria
candida
infect
indwel
devic
caus
variabl
number
often
numer
pulmonari
nodul
serum
test
fungal
antigen
galactomannan
per
form
nodul
caus
pyogen
bacteri
viral
pneu
monia
tend
associ
radiograph
chang
find
ground
glass
infiltr
consolid
infect
episod
main
risk
factor
neutropenia
cellmedi
immun
defect
func
tional
defect
phagocyt
respons
due
cytotox
immunosuppress
therapi
also
markedli
increas
risk
develop
pneumonia
antibodi
defici
asso
ciat
lymphoprolif
disord
myeloma
hsct
predispos
affect
patient
develop
pneumonia
encapsul
organ
pneumonia
haemophilu
influenza
mani
case
bacteri
pneumonia
nosocomi
infect
patient
hospit
long
period
previous
treat
antibiot
normal
oropharyng
flora
replac
mainli
gramneg
bacteria
consequ
rang
potenti
organ
caus
bacteri
pneumonia
differ
seen
communityacquir
pneu
monia
high
frequenc
resist
organ
p
aeruginosa
mrsa
see
tabl
bacteri
pneumonia
often
manifest
clinic
pictur
similar
seen
immunocompet
patient
new
onset
fever
cough
chest
radiolog
sign
lobar
consolida
tion
rapid
rise
level
inflammatori
marker
crp
howev
insidi
diffus
present
difficult
differenti
viral
fungal
infect
uncommon
ct
scan
show
dens
focal
consolid
lobar
distribut
help
differenti
bacteri
fungal
viral
pneumonia
figur
blood
cul
ture
posit
case
antigen
test
urin
may
identifi
legionella
pneumophila
pneumonia
infect
patient
atyp
clinic
present
respond
first
secondlin
antibiot
fob
bal
reason
high
diag
nostic
yield
bacteri
pneumonia
protect
specimen
brush
procedur
probabl
add
littl
inform
obtain
direct
bal
histolog
examin
unlik
reveal
specif
featur
lung
biopsi
mainli
use
exclud
caus
lung
infiltr
oxygen
therapi
maintain
normal
pao
essenti
may
requir
continu
posit
airway
pressur
cpap
support
intub
may
necessari
patient
underli
diseas
major
caus
nodul
underli
malign
diseas
lymphoprolif
disord
secondari
prolong
immunosuppress
absenc
ct
sign
suggest
invas
filament
fungal
infect
halo
crescent
sign
nodul
patient
line
infect
posit
blood
cultur
may
treat
empir
metastat
infect
major
patient
lung
nodul
fob
bal
necessari
although
patient
high
risk
infect
invas
filament
fungi
ct
chang
suggest
aspergillu
infect
present
empir
antifung
therapi
reason
altern
strategi
especi
result
fungal
antigen
test
posit
fob
find
unhelp
ful
patient
progress
percutan
ctguid
vat
lung
biopsi
infect
due
fungi
nocardia
mycobacteria
accompani
specif
histopatholog
chang
biopsi
frequent
diagnost
although
mani
immunocompromis
patient
pneumo
nia
hypox
low
platelet
count
andor
abnorm
clot
fob
gener
safe
diagnost
yield
exclus
activ
infect
necessari
make
diagnosi
ip
hsct
even
neg
result
use
experi
peror
fob
perform
without
signific
bleed
patient
platelet
count
bal
perform
patient
mark
hypoxia
sever
tachypnea
care
consid
erat
risk
versu
benefit
procedur
commonli
reduc
pao
mm
hg
may
precipit
need
intub
mechan
ventil
transbronchi
biopsi
improv
diagnost
yield
fob
perhap
often
possibl
patient
need
abl
toler
potenti
complic
pneumothorax
platelet
count
pneumonia
due
bacteri
pathogen
common
lung
infect
immunocompromis
patient
caus
figur
chest
radiograph
show
masslik
consolid
right
middl
lung
zone
patient
acut
myeloid
leukemia
recent
treat
chemotherapi
present
high
temperatur
respiratori
symptom
day
neutropenia
b
comput
tomographi
ct
scan
thorax
patient
show
shadow
due
dens
consolid
right
upper
lobe
smaller
area
consolid
left
upper
lobe
blood
cultur
grew
escherichia
coli
patient
improv
rapidli
appropri
antibiot
suggest
consolid
hospitalacquir
pneumonia
due
e
coli
patient
due
nocardia
like
mycobacteri
infect
nocardi
infect
tend
affect
patient
defect
cell
mediat
immun
hematopoiet
stem
cell
transplant
recipi
median
time
onset
approxim
day
transplant
risk
factor
diseas
also
includ
cor
ticosteroid
use
activ
graftversushost
diseas
concomi
tant
opportunist
infect
especi
cmv
nocardia
infect
manifest
rel
acut
pneu
monia
indol
diseas
similar
infect
mycobacteria
aspergillu
radiolog
chang
includ
patch
consolid
larg
nodul
often
cavit
pleural
involv
third
case
hematogen
spread
organ
brain
joint
soft
tissu
occur
patient
microscopi
histolog
exam
inat
make
diagnosi
rapidli
identif
characterist
bead
branch
gramposit
weakli
acidfast
filament
respiratori
occasion
blood
cultur
posit
requir
prolong
aerob
cultur
nocardia
strain
sensit
cotrimoxazol
well
car
bapenem
amikacin
thirdgener
cephalosporin
tetraci
cline
coamoxiclav
treatment
need
prolong
last
month
immunocompromis
patient
mortal
high
reportedli
cmv
infect
one
import
complic
patient
defect
cellmedi
immun
tran
plant
recipi
patient
receiv
potent
immunosuppr
sive
drug
fludarabin
alemtuzumab
cmv
largest
member
herpesvirida
famili
human
doubl
strand
dna
virus
genom
encod
product
express
replic
three
overlap
phase
hour
term
immedi
earli
earli
late
primari
cmv
infect
common
gener
popula
tion
occur
mainli
children
young
adult
usual
asymptomat
caus
mild
diseas
previou
infect
identifi
serolog
studi
lead
asymptomat
latent
infect
reactiv
immunocompro
mise
person
reactiv
initi
cytokin
tumor
necrosi
factor
stress
catecholamin
viru
often
detect
transplant
recipi
week
infect
episod
involv
anoth
pathogen
around
immunocompromis
patient
neg
result
sero
logic
test
cmv
receiv
transplant
blood
product
contain
leukocyt
cmvposit
donor
develop
cmv
infect
tend
sever
diseas
due
cmv
reactiv
cmvneg
immunocom
promis
patient
also
rare
develop
primari
infect
exposur
someon
activ
cmv
infect
potenti
effect
cmv
reactiv
immunocompro
mise
patient
vari
includ
clinic
asymptom
atic
infect
common
even
immunocompromis
patient
cmv
syndrom
defin
fever
fall
leukocyt
count
increas
transaminas
organspecif
infect
includ
liver
central
nervou
system
cn
gastrointestin
system
lung
often
associ
ate
sever
involv
transplant
organ
accentu
rejectionrel
damag
target
organ
eg
bronchiol
obliteran
lung
transplant
recipi
preclud
mechan
ventil
associ
poor
prognosi
immunocompromis
patient
mortal
rate
initi
antibiot
therapi
effec
tive
local
pattern
hospitalacquir
infect
therefor
probabl
includ
extendedrang
betalactam
aminoglycosid
ciprofloxacin
lack
respons
within
hour
prompt
switch
anoth
broadspectrum
parenter
antibiot
eg
carbapenem
case
caus
pathogen
resist
firstlin
agent
treatment
infec
tion
due
mrsa
resist
gramposit
organ
also
consid
carbapenem
extendedrang
betalactam
usual
good
efficaci
anaerob
organ
antibacteri
prophylaxi
fluoroquinolon
eg
levo
floxacin
often
use
neutropen
phase
hsct
prolong
antibiot
prophylaxi
penicillin
v
encapsul
organ
necessari
patient
ren
dere
function
asplen
diseas
therapi
antibi
otic
prophylaxi
also
may
indic
patient
chronic
graftversushost
diseas
immunoglobulin
defici
bronchiectasi
vaccin
pneumonia
recom
mend
hematopoiet
stem
cell
transplant
recipi
conjug
vaccin
probabl
use
stronger
immunogen
concern
emerg
risk
whoop
cough
recipi
hematopoiet
stem
cell
transplant
perhap
receiv
vaccin
bordetella
pertussi
prophylaxi
azithromycin
expos
infect
case
mycobacteri
infect
usual
associ
defect
cellmedi
immun
tend
develop
subacut
risk
mycobacterium
tuberculosi
infect
strongli
depen
dent
ethnic
background
countri
origin
patient
tuberculosi
consid
atrisk
patient
cellmedi
immun
defect
patchi
nodular
lung
shadow
particularli
highrisk
ethnic
back
ground
nontubercul
mycobacteri
infect
eg
mycobacterium
kansasii
mycobacterium
avium
complex
mac
infrequ
complic
immunocompromis
patient
exclus
diagnosi
neg
cultur
take
long
clinic
use
patient
progress
diseas
therefor
signific
clinic
suspicion
mycobacteri
infect
invas
investig
necessari
obtain
mate
rial
rapid
diagnosi
identif
acidfast
bacilli
specif
histopatholog
chang
possibl
polymeras
chain
reaction
pcr
assay
sampl
obtain
steril
site
treatment
standard
chemotherapi
regimen
nocardia
gramposit
aerob
organ
found
soil
stagnant
water
grow
rel
slowli
branch
fila
ment
immunocompromis
patient
avoid
garden
occup
result
exposur
soil
plant
infec
tion
occur
inhal
patient
wish
con
tinu
garden
may
minim
exposur
wear
protect
cloth
mask
glove
organ
commonli
caus
human
infect
belong
nocardia
asteroid
complex
nocardia
spp
also
caus
diseas
around
lung
infect
immunocompromis
impair
host
immun
increas
incid
oppor
tunist
infect
includ
pneumonia
due
aspergillu
pneumocysti
jirovecii
gramneg
bacteria
nocardia
increas
incid
ebvassoci
lymphoprolif
er
diseas
cmv
pneumon
commonli
manifest
insidi
onset
fever
malais
cough
dyspnea
hypoxia
chest
radiograph
may
normal
appear
show
non
specif
diffus
bilater
infiltr
ct
scan
sensit
identifi
pulmonari
infiltr
classic
show
bibas
symmetr
ground
glass
opac
septal
line
thicken
multipl
small
centrilobular
nodul
figur
asym
metric
chang
consolid
effus
uncom
mon
howev
main
consider
differenti
diagnosi
ip
druginduc
pneumon
patient
receiv
effect
prophylaxi
pcp
serolog
determina
tion
either
igg
igm
place
diagnosi
cmv
diseas
antibodi
mere
reflect
previou
expo
sure
howev
cmv
reactiv
nowaday
readili
detect
identifi
signific
viremia
either
measur
level
antigenemia
cmv
dna
use
pcr
assay
blood
cmv
viremia
usual
detect
day
clinic
manifest
unfortun
cmv
viremia
alway
present
patient
cmv
pneumon
convers
evid
reactiv
necessarili
mean
new
lung
infiltr
due
cmv
pneumon
chanc
cmv
infect
respons
new
lung
infiltr
propor
tional
part
level
cmv
blood
especi
viral
load
increas
rapidli
definit
confirm
cmv
caus
pneumonia
requir
identif
cmv
respiratori
tract
fob
bal
prefer
tran
bronchial
biopsi
possibl
vat
lung
biopsi
presenc
owl
eye
intranuclear
inclus
cytolog
examin
pathognomon
cmv
infect
although
modal
iti
rapid
rel
insensit
test
cmv
cul
ture
respiratori
sampl
use
fibroblast
cell
cultur
look
distinct
cytopathogen
effect
take
least
week
therefor
littl
clinic
benefit
main
diagnost
techniqu
cmv
pneumon
rel
sensit
rapid
test
cmv
antigen
use
bal
sampl
directli
indirectli
probe
cell
cultur
inocul
sampl
hour
incub
shell
vial
earli
antigen
detect
assay
quantit
pcr
assay
bal
fluid
use
improv
predict
valu
diagnosi
cmv
pneumon
requir
investig
despit
rang
diagnost
techniqu
wellvalid
standard
identifi
cmv
pneumon
lack
except
vat
biopsi
current
avail
antivir
agent
treatment
cmv
infect
diseas
acyclovir
valacyclovir
ganciclovir
val
ganciclovir
foscarnet
cidofovir
tabl
regimen
base
purin
analogu
ganciclovir
prefer
treat
ment
agent
phosphoryl
within
infect
cell
competit
inhibit
viral
dna
polymeras
ganciclovir
signific
marrowdepress
effect
may
toxic
use
hematopoiet
stem
cell
transplant
recipi
patient
exist
pancytopenia
oral
absorpt
poor
oral
therapi
valin
ester
valganciclovir
excel
lent
bioavail
secondlin
agent
foscarnet
also
inhibit
activ
viral
dna
polymeras
bind
pyrophosphatebind
site
foscarnet
frequent
caus
sig
nific
renal
toxic
altern
cidofovir
broad
activ
iti
dna
virus
includ
cmv
act
competit
inhibitor
viral
dna
polymeras
cidofovir
caus
myelosuppress
renal
toxic
patient
prehydr
given
proben
initi
treat
ment
patient
cmv
diseas
also
frequent
given
hyperimmun
intraven
immunoglobulin
ivig
passiv
vaccin
therapi
studi
compar
drug
efficaci
cmv
pneumonia
treatment
last
day
guid
blood
test
measur
level
cmv
viremia
patient
risk
infect
often
given
antivir
prophylaxi
valganciclovir
mortal
rate
establish
cmv
pneumonia
hematopoiet
stem
cell
transplant
recipi
less
type
immunocompromis
patient
detect
cmv
viremia
frequent
lead
preemptiv
therapi
symptomat
cmv
infect
develop
increas
number
patient
requir
treatment
improv
overal
outcom
herp
simplex
viru
hsv
varicellazost
viru
vzv
rare
caus
lung
infect
immunocompromis
patient
present
similar
cmv
pneumo
nia
patient
also
may
characterist
skin
involv
ment
microbiolog
diagnosi
reli
isol
viru
skin
lesion
bal
fluid
treatment
highdos
acyclovir
human
herpesviru
type
may
import
pathogen
caus
infect
hsct
patient
viremia
cmv
reactiv
unex
plain
fever
rash
compar
patient
without
viremia
highlevel
viremia
copi
ml
associ
cultureneg
pneumon
lower
respiratori
tract
infect
respiratori
virus
rel
common
immunocompromis
patient
common
relev
virus
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
serotyp
iii
influenza
viru
adenoviru
human
metapneumoviru
coronaviru
possi
bli
rhinoviru
infect
acquir
inhal
infect
respiratori
droplet
infect
patient
mildli
affect
immunocompet
contact
consequ
immuno
compromis
patient
avoid
contact
social
contact
member
hospit
staff
clearli
suffer
upper
respiratori
tract
infect
nosocomi
epidem
respiratori
virus
readili
occur
infect
patient
effect
isol
respiratori
viral
infect
associ
defect
cellmedi
immun
gener
late
complic
hsct
respiratori
viru
lung
infect
often
caus
bronchiol
manifest
cough
fever
wheez
inspiratori
squeak
frequent
preced
day
coryz
symp
tom
chest
radiograph
may
normal
appear
ct
scan
show
evid
small
airway
involv
widespread
treeinbud
chang
figur
main
consider
differenti
diagnosi
clinic
sce
nario
chlamydia
mycoplasma
infect
extens
bact
rial
bronchiti
usual
associ
bronchiectasi
possibl
aspergillu
tracheobronch
sever
diseas
associ
signific
pneumon
ct
evid
includ
small
poorli
defin
centrilobular
nodul
usual
bilater
patchi
area
peribronchi
ground
glass
opac
consolid
differenti
diagnosi
case
much
broader
scope
includ
bacteri
pneumonia
cmv
pneu
moniti
pcp
noninfect
caus
pneumon
mani
patient
diagnosi
respiratori
viral
infect
rapidli
confirm
noninvas
test
use
nasopharyng
aspir
sampl
either
immunofluoresc
viral
anti
gen
pcr
assay
viral
nucleic
acid
neg
result
nasopharyng
aspir
studi
lead
fob
test
sensit
bal
fluid
naso
pharyng
aspir
sampl
respiratori
viral
infect
immunocompromis
patient
often
prolong
show
treeinbud
chang
obviou
right
upper
lobe
due
piv
serotyp
bronchiol
patient
relaps
acut
myeloid
leukemia
complet
chemotherapi
day
previous
present
coryz
symptom
cough
mild
fever
piv
parainfluenza
viru
sever
symptom
posit
result
nasopha
ryngeal
aspir
studi
persist
sever
week
except
influenza
treatment
option
respira
tori
virus
limit
depend
underli
viru
see
tabl
absenc
pneumonia
mortal
associ
ate
respiratori
viru
infect
immunocompromis
antivir
drug
therapi
adenovir
infect
per
form
avail
data
suggest
cidofovir
ribavirin
may
efficaci
respiratori
viral
infect
earli
hematopoiet
cell
tran
plantat
predictor
develop
alloim
mune
lung
syndrom
progress
airway
obstruct
due
bronchiol
obliteran
perhap
sensit
respiratori
epithelium
lung
involv
graftversu
host
diseas
clinic
patient
present
rapidli
pro
gressiv
airway
obstruct
context
activ
respiratori
viral
infect
requir
aggress
immunosuppress
prevent
progress
respiratori
failur
invas
infect
aspergillu
constitut
common
import
caus
lung
infect
immunodefici
patient
aspergillu
organ
saprophyt
filament
fungi
found
ubiquit
environ
propag
dispers
airborn
spore
diamet
therefor
reach
distal
airway
exposur
airborn
spore
essenti
continu
rare
caus
clinic
problem
unless
host
immun
respons
impair
patient
impair
macrophag
neutrophil
function
howev
spore
germin
form
coloni
branch
ing
multicellular
hypha
gradual
expand
penetr
host
tissu
caus
invas
pulmonari
aspergillosi
ipa
usual
site
infect
respiratori
tract
includ
ing
sinus
bloodborn
spread
intern
organ
especi
cn
bone
skin
common
frequent
isol
speci
caus
infect
fumigatu
case
aspergillu
flavu
aspergillu
niger
aspergillu
terreu
ipa
mainli
diseas
affect
patient
hematolog
malign
receiv
chemotherapi
person
aplast
anemia
transplant
recipi
earli
phase
hsct
signific
persist
neutropenia
strongest
risk
factor
incid
proport
depth
durat
neutropenia
patient
neutro
penia
last
week
develop
ipa
patient
high
risk
also
includ
receiv
highdos
system
corticost
roid
therapi
andor
graftversushost
diseas
caus
ipa
late
phase
hsct
lung
liver
transplant
recipi
ent
patient
inherit
disord
phagocyt
func
tion
chronic
granulomat
diseas
cgd
mutat
gene
encod
nadph
oxidas
system
impair
phagocyt
oxid
burst
variou
genet
polymor
phism
affect
tolllik
receptor
tlr
cytokin
seem
modifi
risk
invas
aspergillosi
patient
risk
group
speed
develop
ipa
proport
level
immunosuppress
diseas
usual
evolv
rela
tive
slowli
day
week
fever
may
symptom
ipa
although
cough
pleurit
chest
pain
hemoptysi
common
chest
radiograph
show
expand
patch
irregular
consolid
often
infarct
shape
nodul
cavit
ct
scan
help
defin
nodular
natur
infiltr
may
show
specif
sign
associ
ipa
identifi
lung
patient
rel
low
patient
given
support
therapi
contrast
pneumonia
due
respiratori
virus
hsct
associ
signific
mortal
secondari
infect
common
patient
frequent
need
concurr
treatment
antibiot
influenza
virus
infect
hsct
influenza
virus
perhap
surprisingli
less
common
infect
rsv
piv
firstlin
therapi
neuraminidas
inhibi
tor
zanamivir
oseltamivir
seem
effect
limit
diseas
sever
durat
altern
agent
treatment
influenza
viru
infect
amantidin
efficaci
clear
transplant
recipi
famili
member
household
contact
receiv
lifelong
sea
sonal
influenza
vaccin
trival
inactiv
vaccin
outbreak
occur
nonvaccin
influenza
strain
chemoprophylaxi
zanamivir
oseltamivir
consid
although
infect
piv
probabl
among
common
caus
respiratori
viral
infect
hsct
current
data
effect
treatment
scarc
ribavarin
ivig
may
activ
piv
infect
yet
shown
benefici
clinic
practic
use
vaccin
gener
avail
yet
hematopoiet
stem
cell
tran
plant
recipi
particularli
preengraft
lymphopen
preexist
obstruct
airway
diseas
highest
risk
sever
rsv
pneumonia
therapi
rsv
infect
includ
system
aerosol
ribavirin
passiv
immun
highrsvtit
immunoglobulin
monoclon
antibodi
direct
rsv
f
antigen
palivi
zumab
random
trial
complet
test
efficaci
strategi
efficaci
data
limit
center
provid
monthli
palivizumab
prophylaxi
hemato
poietic
stem
cell
transplant
recipi
rsv
season
novemb
april
northern
hemispher
particularli
pediatr
recipi
preemptiv
aerosol
ribavirin
may
effect
transplant
recipi
lymphopenia
preexist
impair
lung
function
develop
rsv
upper
respiratori
tract
infect
emerg
evi
denc
infect
spread
lung
human
metapneumoviru
hmpv
rel
recent
identifi
rna
paramyxoviru
relat
rsv
increasingli
associ
lower
respiratori
tract
infect
pneumonia
hematopoiet
stem
cell
transplant
recipi
mortal
rate
ivig
ribavirin
vitro
activ
hmpv
recommend
treatment
current
avail
owe
lack
data
adenoviru
adenoviru
infect
occur
patient
impair
cellmedi
immun
due
reactiv
de
novo
acquisit
mani
differ
adenoviru
serotyp
exist
pretranspl
serolog
help
hsct
risk
adenoviru
infect
increas
allograft
recipi
cell
deplet
treatment
antithymocyt
globulin
alem
tuzumab
patient
graftversushost
diseas
receiv
system
steroid
clearanc
adenoviru
shown
associ
recoveri
adenovirusspecif
cell
immun
antivir
agent
vivo
activ
adenovirus
random
placebocontrol
studi
sourc
infect
patient
pyrexia
normal
chest
radiograph
specif
ct
appear
ipa
includ
halo
sign
area
lower
attenu
shadow
around
nodul
patch
consolid
report
case
ipa
usual
occur
first
week
infect
figur
air
crescent
sign
partial
caviti
form
infarct
necrot
lung
specif
lateronset
sign
occur
around
third
week
infect
intrapulmonari
caviti
contain
fungal
ball
especi
associ
recoveri
patient
neutrophil
count
see
figur
halo
sign
may
detect
infect
neo
plasm
adenocarcinoma
bronchoalveolar
carcinoma
kaposi
sarcoma
metastas
vascul
aspergillu
predilect
grow
blood
vessel
patient
ipa
may
suffer
fatal
massiv
hemorrhag
manifest
invas
aspergillu
infect
affect
lung
includ
aspergillu
tracheobronch
chronic
necrot
pulmonari
aspergillosi
cnpa
chronic
cavitari
pulmonari
aspergil
losi
ccpa
aspergillu
tracheobronch
infect
restrict
tracheobronchi
tree
manifest
sever
unremit
ting
cough
pyrexia
ct
scan
may
show
focal
area
bronchial
wall
thicken
treeinbud
small
airway
diseas
figur
fob
usual
diagnost
distinct
macroscop
appear
patchi
highli
inflam
mucosa
necrot
white
slough
aspergillu
found
cultur
andor
cytolog
bronchial
wash
may
evi
denc
fungal
invas
respiratori
mucosa
bronchial
biopsi
specimen
indol
form
invas
aspergillosi
ccpa
cnpa
increas
incid
associ
milder
degre
immunosuppress
includ
steroid
cytotox
therapi
chronic
lung
diseas
cystic
fibrosi
affect
patient
present
long
histori
cough
mark
system
symptom
malais
fatigu
weight
loss
chest
radiograph
cnpa
manifest
indol
patch
consolid
without
cavit
progress
week
month
figur
wherea
ccpa
manifest
expand
upper
lobe
dri
caviti
thicken
irregular
wall
may
associ
pleural
thicken
aspergillu
infect
also
caus
progress
upper
lobe
fibrosi
b
figur
comput
tomographi
ct
scan
thorax
patient
acut
lymphocyt
leukemia
treat
chemotherapi
present
persist
cough
fever
scan
show
asymmetr
treeinbud
nodular
chang
mainli
affect
right
upper
lobe
caus
aspergillu
tracheobronch
investig
help
make
diagnosi
ipa
describ
b
histopatholog
examin
sampl
readili
identifi
fungal
hypha
infiltr
lung
tissu
fungal
stain
use
henc
strong
consider
given
biopsi
lung
nodul
respond
convent
antibacteri
antibiot
especi
bal
nondiagnost
decreas
mortal
allow
rapid
identif
case
ipa
fungal
load
high
sever
noninvas
test
develop
includ
detect
galactomannan
glucan
cell
wall
antigen
blood
bal
fluid
fob
perform
pcr
assay
aspergillu
dna
blood
bal
fluid
test
highli
sensit
use
surveil
highrisk
patient
could
lead
preemp
tive
antifung
therapi
clinic
appar
diseas
develop
lead
improv
mortal
howev
detec
tion
fungal
dna
singl
sampl
peripher
blood
poor
indic
earli
invas
fungal
infect
galacto
mannan
antigen
specif
aspergillu
spp
frequent
give
falseposit
result
especi
patient
treat
piperacillintazobactam
young
children
despit
caveat
neg
galactomannan
assay
result
make
activ
ipa
infect
unlik
serolog
test
antibodi
aspergillu
usual
yield
neg
result
immunocompromis
patient
ipa
diagnos
chronic
form
ipa
less
immunocompro
mise
patient
often
difficult
owe
lack
sensit
cultur
lack
data
predict
valu
antigen
test
ctguid
vat
biopsi
frequent
necessari
exclud
malign
confirm
fungal
invas
lung
tissu
aspergillu
igg
level
usual
rais
patient
ccpa
necessarili
cnpa
azol
use
prophylaxi
atrisk
group
includ
hematopoiet
stem
cell
transplant
recipi
fluconazol
effect
prevent
mold
infect
ipa
despit
efficaci
aspergillu
voriconazol
seem
offer
clinic
benefit
prophylaxi
fluconazol
howev
prophylaxi
newer
extendedspectrum
tri
azol
posaconazol
reduc
incid
invas
asper
gillosi
patient
prolong
neutropenia
acquir
resist
fumigatu
posaconazol
emerg
cours
therapi
may
potenti
limit
use
prophylaxi
although
aspergillu
spp
domin
infect
due
mold
filament
fungi
caus
invas
pulmonari
infec
tion
immunocompromis
patient
includ
fusarium
zygomycet
scedosporium
penicillium
infect
often
clinic
similar
invas
aspergillosi
differ
spectrum
suscept
antifung
agent
henc
nonaspergillu
filament
fungal
infect
need
consid
patient
clinic
diagnosi
ipa
respond
antifung
therapi
diagnosi
made
cultur
respiratori
sampl
lung
biopsi
mortal
high
galactomannan
cell
wall
antigen
test
result
neg
patient
infect
zygomycet
treatment
surgic
combin
ampho
tericin
infect
due
fusarium
scedosporium
zygomycet
voriconazol
posaconazol
infect
candida
rare
manifest
pneumonia
candidemia
may
lead
metastat
lung
infect
caus
treatment
option
invas
aspergillosi
con
sider
improv
introduct
new
azol
voricon
azol
recent
posaconazol
new
class
antifung
agent
echinocandin
first
exampl
caspofungin
dose
mode
action
common
toxic
differ
treatment
option
given
tabl
voriconazol
may
effect
amphotericin
b
treat
ipa
drug
use
depend
patient
toler
agent
preexist
medic
condit
eg
amphotericin
b
avoid
patient
renal
problem
azol
patient
liver
diseas
itracon
azol
less
efficaci
reserv
oral
treat
ment
patient
recov
ipa
induct
treatment
amphotericin
b
caspofungin
voriconazol
longterm
treatment
requir
chronic
form
invas
aspergillosi
drug
level
probabl
monitor
patient
receiv
itraconazol
voriconazol
posaconazol
least
patient
prolong
therapi
role
combina
tion
therapi
remain
unclear
strategi
potenti
attract
view
differ
mechan
action
three
effect
class
drug
urgent
surgic
resect
consid
patient
major
hemoptysi
fatal
bleed
uncommon
elect
resect
use
primari
therapi
singl
lesion
due
ipa
especi
contain
intracavitari
mycetoma
might
lead
reac
tivat
ipa
subsequ
immunosuppress
treat
ment
ipa
sever
week
often
necessari
follow
prophylact
therapi
case
persist
radiolog
chang
treatment
cnpa
ccpa
need
continu
month
year
even
lifelong
owe
combina
tion
uncontrol
infect
underli
diseas
mortal
rate
ipa
around
chronic
form
aspergillosi
infect
rate
remain
high
atrisk
patient
confirm
cytolog
identif
characterist
p
jirovecii
cyst
bal
fluid
diagnosi
improv
use
immunohistochemistri
assay
pneumocysti
antigen
perhap
pcr
analysi
although
latter
signific
falseposit
rate
consequ
colon
absenc
diseas
firstlin
treatment
highdos
cotrimoxazol
adjuv
steroid
given
accord
protocol
use
pcp
hivinfect
patient
myelosuppress
due
cotrimoxazol
mean
mani
patient
hematolog
disord
switch
secondlin
therapi
clindami
cin
primaquin
nonhiv
immunocompromis
patient
pcp
associ
intub
mortal
rate
around
pcp
prophylaxi
usual
prescrib
sever
month
allograft
hsct
organ
transplant
occasion
longer
patient
continu
receiv
immu
nosuppress
drug
patient
recov
pcp
con
tinu
chemoprophylaxi
immunosuppress
resolv
although
clear
paramet
defin
endpoint
consensu
lack
requir
pcp
prophylaxi
autograft
hsct
sever
nontransplantationrel
immunosuppress
cotrimoxazol
prophylaxi
given
either
daili
three
time
per
week
effect
greater
efficaci
provid
protec
tion
pathogen
includ
toxoplasma
nocardia
bacteria
exactli
bronchoscopi
use
diagnos
respiratori
infect
immunocompromis
patient
remain
controversi
clear
consensu
earli
versu
late
bronchoscopi
approach
describ
chapter
base
type
lung
shadow
aim
target
bronchoscopi
patient
may
help
cmv
pneumon
especi
difficult
diagnosi
confirm
specif
diagnost
test
often
inconclus
clinician
left
presumpt
evid
involv
cmv
consist
combin
pneumon
blood
test
result
indic
reactiv
viru
major
pitfal
avoid
failur
consid
noninfect
caus
respiratori
problem
nonhivinfect
immunocompromis
patient
pulmonari
edema
alveolar
hemorrhag
ard
drugrel
idiopath
pneumon
rapidli
progress
airway
obstruct
due
lung
graft
versushost
diseas
often
precipit
respiratori
viral
infect
often
need
includ
differenti
diagnosi
although
infect
caus
lung
problem
nonhivinfect
immunocompromis
patient
gener
fairli
characterist
present
affect
select
risk
group
consider
overlap
clinic
presenta
tion
ill
due
specif
infecti
agent
typic
especi
true
sever
immunosup
press
patient
usual
clinic
present
becom
less
characterist
final
clinician
need
rememb
nonhiv
infect
immunocompromis
patient
often
two
simultan
patholog
condit
eg
bacteri
pneu
monia
complic
ard
respiratori
viral
infect
lung
graftversushost
diseas
pyrexia
associ
radiolog
evid
lung
nodul
often
peripher
locat
sometim
larg
neutropen
patient
mucos
indwel
line
risk
invas
candidemia
usual
caus
dissemin
endogen
colon
candida
spp
frequent
use
fluconazol
prophylaxi
led
increas
isol
nonalbican
speci
candida
glabrata
candida
parapsilosi
treatment
caspofungin
ampho
tericin
voriconazol
posaconazol
cryptococcu
neoforman
infect
acquir
inhal
fungal
spore
although
respiratori
infect
often
asymptomat
cryptococc
diseas
caus
multifoc
con
solid
sever
pneumonia
patient
defect
cellmedi
immun
carri
mortal
rate
diagnosi
made
microscop
identif
cultur
c
neoforman
respiratori
tract
sampl
treatment
intraven
amphotericin
b
combin
flucyto
sine
follow
oral
fluconazol
reactiv
latent
infec
tion
endem
fungi
histoplasma
coccidioid
consid
patient
defect
cellmedi
immun
present
multifoc
lung
shadow
live
relev
geograph
area
especi
evid
extrapulmonari
involv
diagnosi
gener
requir
identif
fungu
tissu
sampl
addit
close
associ
hiv
infect
pcp
import
type
pneumonia
nonhivinfect
immu
nocompromis
patient
defect
cellmedi
immu
niti
receiv
system
corticosteroid
therapi
equival
greater
mg
daili
prednisolon
clinic
present
gener
insidi
onset
cough
progress
dyspnea
develop
week
fulmin
impair
ga
transfer
hypoxia
exert
progress
respiratori
failur
common
chest
radiograph
usual
show
bilater
infiltr
may
normal
appear
gener
ct
scan
show
ground
glass
infiltr
classic
mainli
affect
upper
lobe
spare
lung
peripheri
figur
rare
occas
howev
even
ct
scan
may
show
minim
abnormali
tie
diagnosi
made
recognit
clinic
pictur
